PharmaFocus Today – Page 153 – media

Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.

BEIJING, SHANGHAI and BOSTON, March 1, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND in China, and will conduct clinical studies once receives the IND approval. P53 is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% of all invasive tumors. JAB-30300 is an orally bioavailable small molecule activator for the treatment of patients with solid tumors harboring P53 Y220C mutation. Studies shows that, JAB-30300 has shown very high binding affinity to P53 Y220C mutant proteins. Tumor regression was achieved in multiple cancer models covering various ...
- Source: drugdu
- 150
- March 5, 2024
WuXi Biologics’ Irish Site Awarded Three Authoritative ISO International Standard System Certifications

Dundalk, Ireland, March 1, 2024 – WuXi Biologics (2269.HK), a leading global contract research, development and manufacturing (CRDMO) services company, announced that its Dundalk, Ireland site has recently been awarded three authoritative ISO (International Organization for Standardization) accreditations at the same time, including ISO 50001 Energy Management System, ISO 14001 Environmental Management System and ISO 45001 Occupational Health and Safety Management System. ISO 50001 Energy Management System Certification, ISO 14001 Environmental Management System Certification and ISO 45001 Occupational Health and Safety Management System Certification, fully demonstrating that WuXi Biologics has always been adhering to the ESG (Environmental, Social and Governance) development strategy, and has consistently adhered to international standards and achieved outstanding results in environmental protection, sustainable energy development and employee health and safety. As a model for WuXi Biologics’ future factory, the Ireland site has been actively optimizing energy use, improving efficiency and reducing waste emissions from operations, and ...
- Source: drugdu
- 82
- March 5, 2024
Researchers reveal COVID-19 could have small impacts on cognition and memory

Different factors, such as illness duration and virus variant, impacted patients cognitive abilities Imperial College London (ICL) researchers have revealed that people who have recovered from COVID-19 could have small but long-lasting impacts on the performance of cognitive and memory tasks. Published in the New England Journal of Medicine, the REACT Long COVID study enrolled over 140,000 participants, including long COVID patients, who undertook at least one cognitive task. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. For some patients, the condition can lead to long COVID, where symptoms can last up to 12 weeks. Using an innovative online cognitive assessment via the Cognitron platform, researchers detected subtle changes in different areas of brain function, including memory, reasoning, executive function, attention and impulsivity. The study revealed small deficits that were still detectable after a year or more following infection, including in people who had a short duration of ...
- Source: drugdu
- 93
- March 5, 2024
ICL uses AI to help doctors assess lung cancer from ‘virtual biopsies’

TMR-CT will help doctors select treatment and predict the spread of lung cancer in patients Imperial College London (ICL) researchers have used artificial intelligence (AI) to identify information about the chemical makeup of lung tumours from medical scans of lung cancer. Published in npj Precision Oncology, the study demonstrates, for the first time, how medical imaging in combination with AI can be used to provide ‘virtual biopsies’ for cancer patients. Responsible for around 35,000 deaths each year, lung cancer is the most common cause of cancer death in the UK. Supported with funding from the National Institute for Health and Care Research’s Imperial Biomedical Research Centre, the non-invasive method works to classify the type of lung cancer patients have. Researchers used data from 48 lung cancer patients recruited from University Hospital Reina Sofia in Spain to develop an AI-powered, deep learning assessment tool called tissue-metabolomic-radiomic-CT (TMR-CT). Using the data, researchers ...
- Source: drugdu
- 70
- March 5, 2024
Pfizer’s Bivalent Respiratory Syncytial Virus Vaccine Shows Promising Efficacy Across Two Seasons

Davy James Abrysvo was found to produce durable efficacy against respiratory syncytial virus across two seasons in adults 60 years of age and older. Top-line data from the ongoing, pivotal Phase III RENOIR clinical trial (NCT05035212) demonstrated that Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo produces durable efficacy against respiratory syncytial virus (RSV) across two seasons in adults 60 years of age and older. Efficacy against RSV-associated lower respiratory tract disease (LRTD), defined as three or more symptoms, was 88.9% after the first season, whereas efficacy was 77.8% after the second season.1 “We are encouraged by the level of protection that we observed after two full RSV seasons for Abrysvo,” Annaliesa Anderson, PhD, Pfizer senior vice president and chief scientific officer, Vaccine Research and Development, said in a press release. “This new data indicate that broad and durable protection against both types of RSV that cause ...
- Source: drugdu
- 153
- March 4, 2024
Profound Medical, Siemens Healthineers collab on ultrasound ablation

Profound Medical (Nasdaq:PROF) announced today that it entered into a non-exclusive collaboration with Siemens Healthineers. The two companies aim to lay the groundwork for Profound to begin marketing a complete therapeutics solution. They want to combine the Profound TULSA-PRO system with the Siemens Magnetom Free.Max magnetic resonance (MR) scanner. While this combination falls under the remit of Profound’s own sales force, the company also plan to market TULSA-PRO as a standalone offering. This enables customers to use the technology with the MR hardware of their choice. TULSA-PRO performs the company’s transurethral ultrasound ablation (TULSA) procedure. It employs real-time MR guidance for precision while killing targeted prostate tissue through sound absorption technology. The system enables surgeons to ablate whole- or partial-gland prostate tissue in patients with low- intermediate- or high-risk prostate cancer. It also treats benign prostatic hyperplasia (BPH). It can treat prostate cancer patients on active surveillance seeking treatment of ...
- Source: drugdu
- 89
- March 4, 2024
Tandem cycling boosts well-being for Parkinson’s patients and care partners

Pedaling on a stationary bicycle built for two may improve the health and well-being for both people with Parkinson’s disease and their care partners, according to a small, preliminary study released today, February 29, 2024, that will be presented at the American Academy of Neurology’s 76th Annual Meeting taking place April 13–18, 2024, in person in Denver and online. Jennifer Trilk, PhD, University of South Carolina School of Medicine in Greenville, said, “Our study found that a unique cycling program that pairs people with Parkinson’s disease with their care partners can improve the physical, emotional and mental well-being of both cyclists to improve their quality of life. It is just as important that care partners also receive care, so that is why we included them as the cycling partner. The goal of our small study was to determine if tandem cycling was beneficial. The next step will be to confirm ...
- Source: drugdu
- 95
- March 4, 2024
Comprehensive protein analysis reveals potential targets for treating dialysis-related amyloidosis

Dialysis patients often develop dialysis-related amyloidosis and exhibit bone and joint disorders that impair their activity of daily living. Blood purification devices consisting of hexadecyl-immobilized cellulose beads aimed at removing the precursor protein, β2- microglobulin (β2-m), are used in the treatment of dialysis-related amyloidosis. Dr. Yamamoto et al. investigated that comprehensive analysis of proteins adsorbed onto blood purification devices revealed the identification of 200 types of proteins, including β2-m. Among these, several molecules, such as lysozyme, were shown to be involved in amyloid fibril formation. I. Background of the study Patients with advanced chronic kidney disease (CKD) require kidney replacement therapy, such as hemodialysis, to manage their condition. Hemodialysis patients often experience various symptoms, leading to a compromised quality of life and reduced activity levels. Itching is a common symptom frequently observed in hemodialysis patients. Although its exact causes remain unclear, a survey conducted in Japan in 2000 found that ...
- Source: drugdu
- 133
- March 4, 2024
CHMP recommends Travere and CSL Vifor’s Filspari to treat rare kidney disease IgAN

The European Medicines Agency’s (EMA) human medicine committee has recommended Travere Therapeutics and CSL Vifor’s Filspari (sparsentan) for approval as a treatment for adults with primary IgA nephropathy (IgAN), a rare form of kidney disease. If approved, Filspari will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN in Europe. Estimated to affect around 25 per million adults worldwide, IgAN is the most common type of primary glomerular disease worldwide and the current leading cause of kidney failure. The condition occurs when the immunoglobulin A (IgA) protein becomes trapped in the very fine filters of the kidney, resulting in damage and scarring to the kidney. The Committee for Medicinal Products for Human Use (CHMP) has recommended Filspari as treatment in adults with primary IgAN with a urine protein excretion above 1g/day. The recommendation was based on results from the pivotal phase 3 PROTECT study, ...
- Source: drugdu
- 120
- March 2, 2024
New Hantavirus Rapid Test Paves Way for Early Outbreak Control

Orthohantaviruses, known for their ability to cause hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syndrome in the Americas, are significant public health concerns due to their high transmission rates and impact on health. These zoonotic pathogens have been the focus of extensive research, particularly for controlling outbreaks and devising intervention strategies. In South Korea’s Gyeonggi Province, a notable number of HFRS cases have been reported, highlighting the need for diligent epidemiological surveillance and a deeper understanding of orthohantaviruses’ genomic diversity. Now, new research has unveiled the potential of cost-efficient Flongle sequencing for rapid hantavirus genome-based diagnostics and phylogeographical surveillance. A research team from Korea University College of Medicine (Seoul, South Korea) undertook a study in the Gyeonggi Province to investigate the prevalence, viral loads, and genetic variations of Hantaan orthohantavirus (HTNV). They utilized Flongle sequencing, an innovative and budget-friendly approach, for detecting HTNV genomes, emphasizing the ...
- Source: drugdu
- 105
- March 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.